541 related articles for article (PubMed ID: 27184811)
1. Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.
Antonarakis ES; Armstrong AJ; Dehm SM; Luo J
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):231-41. PubMed ID: 27184811
[TBL] [Abstract][Full Text] [Related]
2. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor splice variants in the era of enzalutamide and abiraterone.
Nakazawa M; Antonarakis ES; Luo J
Horm Cancer; 2014 Oct; 5(5):265-73. PubMed ID: 25048254
[TBL] [Abstract][Full Text] [Related]
5. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations.
Lu C; Brown LC; Antonarakis ES; Armstrong AJ; Luo J
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):381-397. PubMed ID: 32139878
[TBL] [Abstract][Full Text] [Related]
7. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.
Watson PA; Chen YF; Balbas MD; Wongvipat J; Socci ND; Viale A; Kim K; Sawyers CL
Proc Natl Acad Sci U S A; 2010 Sep; 107(39):16759-65. PubMed ID: 20823238
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.
Yuan X; Cai C; Chen S; Chen S; Yu Z; Balk SP
Oncogene; 2014 May; 33(22):2815-25. PubMed ID: 23752196
[TBL] [Abstract][Full Text] [Related]
9. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.
Yu Z; Chen S; Sowalsky AG; Voznesensky OS; Mostaghel EA; Nelson PS; Cai C; Balk SP
Clin Cancer Res; 2014 Mar; 20(6):1590-600. PubMed ID: 24449822
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
Crona DJ; Milowsky MI; Whang YE
Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
[TBL] [Abstract][Full Text] [Related]
11. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Antonarakis ES; Lu C; Wang H; Luber B; Nakazawa M; Roeser JC; Chen Y; Mohammad TA; Chen Y; Fedor HL; Lotan TL; Zheng Q; De Marzo AM; Isaacs JT; Isaacs WB; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
N Engl J Med; 2014 Sep; 371(11):1028-38. PubMed ID: 25184630
[TBL] [Abstract][Full Text] [Related]
12. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
[TBL] [Abstract][Full Text] [Related]
13. Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells.
Shafi AA; Putluri V; Arnold JM; Tsouko E; Maity S; Roberts JM; Coarfa C; Frigo DE; Putluri N; Sreekumar A; Weigel NL
Oncotarget; 2015 Oct; 6(31):31997-2012. PubMed ID: 26378018
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.
Li Y; Chan SC; Brand LJ; Hwang TH; Silverstein KA; Dehm SM
Cancer Res; 2013 Jan; 73(2):483-9. PubMed ID: 23117885
[TBL] [Abstract][Full Text] [Related]
15. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer.
Bernemann C; Schnoeller TJ; Luedeke M; Steinestel K; Boegemann M; Schrader AJ; Steinestel J
Eur Urol; 2017 Jan; 71(1):1-3. PubMed ID: 27471164
[TBL] [Abstract][Full Text] [Related]
16. Role of androgen receptor splice variants, their clinical relevance and treatment options.
Wach S; Taubert H; Cronauer M
World J Urol; 2020 Mar; 38(3):647-656. PubMed ID: 30659302
[TBL] [Abstract][Full Text] [Related]
17. Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens.
Ylitalo EB; Thysell E; Thellenberg-Karlsson C; Lundholm M; Widmark A; Bergh A; Josefsson A; Brattsand M; Wikström P
Prostate; 2020 Feb; 80(2):214-224. PubMed ID: 31799745
[TBL] [Abstract][Full Text] [Related]
18. CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer.
Bastos DA; Antonarakis ES
Expert Rev Mol Diagn; 2018 Feb; 18(2):155-163. PubMed ID: 29319382
[TBL] [Abstract][Full Text] [Related]
19. Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key?
Antonarakis ES
Expert Rev Anticancer Ther; 2015 Feb; 15(2):143-5. PubMed ID: 25547524
[TBL] [Abstract][Full Text] [Related]
20. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
